These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 10680837)
1. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Motoi F; Sunamura M; Ding L; Duda DG; Yoshida Y; Zhang W; Matsuno S; Hamada H Hum Gene Ther; 2000 Jan; 11(2):223-35. PubMed ID: 10680837 [TBL] [Abstract][Full Text] [Related]
2. Gene therapy for intraperitoneally disseminated pancreatic cancers by Escherichia coli uracil phosphoribosiltransferase (UPRT) gene mediated by restricted replication-competent adenoviral vectors. Oonuma M; Sunamura M; Motoi F; Fukuyama S; Shimamura H; Yamauchi J; Shibuya K; Egawa S; Hamada H; Takeda K; Matsuno S Int J Cancer; 2002 Nov; 102(1):51-9. PubMed ID: 12353234 [TBL] [Abstract][Full Text] [Related]
3. Gene therapy for pancreatic cancer targeting the genomic alterations of tumor suppressor genes using replication-selective oncolytic adenovirus. Sunamura M; Oonuma M; Motoi F; Abe H; Saitoh Y; Hoshida T; Ottomo S; Horii A; Matsuno S Hum Cell; 2002 Sep; 15(3):138-50. PubMed ID: 12703544 [TBL] [Abstract][Full Text] [Related]
4. Oncolytic virotherapy as a novel strategy for pancreatic cancer. Sunamura M; Hamada H; Motoi F; Oonuma M; Abe H; Saitoh Y; Hoshida T; Ottomo S; Omura N; Matsuno S Pancreas; 2004 Apr; 28(3):326-9. PubMed ID: 15084981 [TBL] [Abstract][Full Text] [Related]
5. E1B-deleted adenovirus replicates in p53-deficient lung cancer cells due to the absence of apoptosis. Harada N; Maniwa Y; Yoshimura M; Nagata M; Hamada H; Yokono K; Okita Y Oncol Rep; 2005 Nov; 14(5):1155-63. PubMed ID: 16211279 [TBL] [Abstract][Full Text] [Related]
6. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Shinoura N; Yoshida Y; Tsunoda R; Ohashi M; Zhang W; Asai A; Kirino T; Hamada H Cancer Res; 1999 Jul; 59(14):3411-6. PubMed ID: 10416603 [TBL] [Abstract][Full Text] [Related]
7. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Fukuda K; Abei M; Ugai H; Seo E; Wakayama M; Murata T; Todoroki T; Tanaka N; Hamada H; Yokoyama KK Cancer Res; 2003 Aug; 63(15):4434-40. PubMed ID: 12907616 [TBL] [Abstract][Full Text] [Related]
8. Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. Yoshida Y; Sadata A; Zhang W; Saito K; Shinoura N; Hamada H Hum Gene Ther; 1998 Nov; 9(17):2503-15. PubMed ID: 9853517 [TBL] [Abstract][Full Text] [Related]
9. Experimental studies on treatment of pancreatic cancer with double-regulated duplicative adenovirus AdTPHre-hEndo carrying human endostatin gene. Shan YF; Fang YF; Wang XQ; Jin R; Zhang QY; Andersson R Pancreatology; 2013; 13(4):393-400. PubMed ID: 23890138 [TBL] [Abstract][Full Text] [Related]
10. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. Hay JG; Shapiro N; Sauthoff H; Heitner S; Phupakdi W; Rom WN Hum Gene Ther; 1999 Mar; 10(4):579-90. PubMed ID: 10094201 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Kim J; Cho JY; Kim JH; Jung KC; Yun CO Cancer Gene Ther; 2002 Sep; 9(9):725-36. PubMed ID: 12189522 [TBL] [Abstract][Full Text] [Related]
12. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. Ohashi M; Kanai F; Tateishi K; Taniguchi H; Marignani PA; Yoshida Y; Shiratori Y; Hamada H; Omata M Biochem Biophys Res Commun; 2001 Mar; 282(2):529-35. PubMed ID: 11401492 [TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Dehari H; Ito Y; Nakamura T; Kobune M; Sasaki K; Yonekura N; Kohama G; Hamada H Cancer Gene Ther; 2003 Jan; 10(1):75-85. PubMed ID: 12489031 [TBL] [Abstract][Full Text] [Related]
14. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Liu XY; Qiu SB; Zou WG; Pei ZF; Gu JF; Luo CX; Ruan HM; Chen Y; Qi YP; Qian C Mol Ther; 2005 Apr; 11(4):531-41. PubMed ID: 15771956 [TBL] [Abstract][Full Text] [Related]